Related Experiment Video

Updated: Apr 17, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.7K

Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer

A S Abdelmoneim1, D T Eurich2, P E Light3

  • 1Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada.

Diabetes, Obesity & Metabolism
|February 26, 2015
PubMed

Insights

The cardiovascular safety of sulfonylureas remains debated, with conflicting evidence from observational and clinical studies. Further research is needed to clarify the risks of these diabetes medications.

Area of Science:

  • Endocrinology
  • Cardiology
  • Pharmacology

Background:

  • The cardiovascular safety of sulfonylureas has been debated for over 40 years since the University Group Diabetes Program trial.
  • Existing hypotheses linking sulfonylureas to adverse cardiovascular effects lack conclusive evidence.
  • Current research presents inconsistent findings regarding the cardiovascular impact of sulfonylureas.

Purpose of the Study:

  • To review the ongoing controversy surrounding sulfonylurea cardiovascular safety.
  • To critically analyze the limitations within existing literature on this topic.
  • To propose recommendations for future research to definitively establish the cardiovascular effects of sulfonylureas in type 2 diabetes.

Main Methods:

  • Review and synthesis of existing clinical trials and observational studies.
  • Analysis of data limitations, including confounding and bias in observational studies.
  • Evaluation of the design and scope of previous randomized controlled trials.

Main Results:

  • Observational studies suggest an increased risk of adverse cardiovascular outcomes with sulfonylureas, though potentially confounded.
  • Randomized controlled trials generally indicate a neutral cardiovascular effect, but often lack specific design for this outcome.
  • Ongoing large clinical trials are expected to provide further insights, but results are years away.

Conclusions:

  • The cardiovascular safety of sulfonylureas remains uncertain due to conflicting and limited evidence.
  • Methodological limitations in current studies hinder definitive conclusions.
  • Future research with robust designs is essential to resolve the controversy and guide clinical practice for type 2 diabetes management.

Keywords:
cardiovascular diseasesulphonylureas

More Related Videos

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.8K
In Silico Clinical Trials for Cardiovascular Disease09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.4K

Related Concept Videos

Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.7K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
990
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
995
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
379
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
909